Surgery Websites
Bariatric Surgery »  Research »  Clinical Trials »  EndoSurgery

Endoscopic Surgery for Bariatric Revision After Weight Loss Failure

Official Title:

Apollo OverStitch for Bariatric Surgery Revision After Weight Loss Failure

Basic Trial Information

Phase Type Age Sponsor Protocol IDs Status
N/A Interventional 18 Years and older University of California, San Francisco EndoSurgery
Enrolling patients

Study Design:

Principal Investigator

Professor of Surgery
Division of General Surgery
Director, UCSF Surgery Clerkship Program

Matthew Y.C. Lin, MD
[email protected]

Trial Summary

Morbid obesity and its associated metabolic diseases are on the rise in the United States. Currently, the best treatment for obesity is bariatric surgery where both roux-en-Y gastric bypass and sleeve gastrectomy offer substantial weight loss. Unfortunately, 20% of patients who undergo bariatric surgery fail to lose enough weight defined as less than 50% of excess body weight loss or regain of weight. For those patients who fail to lose weight after bariatric surgery and have failed maximal medical therapy and diet supervision, the treatment is re-operation and revision. Re-operation of the abdomen carries significant postoperative morbidity and mortality. The investigators propose to use the Apollo OverStitch endoscopic suturing device that has already been approved by the FDA as an option for bariatric surgery revision without having to re-operate on the patient. The investigators believe that the endoscopic technique may be able to provide weight loss without having to re-operate on the patient.


Inclusion Criteria:
  • Previous Roux-En-Y Gastric Bypass (RYGB) or Sleeve Gastrectomy (SG)
  • Failure to lose >50% of their excess body weight after 1 year
  • Failure of weight loss despite maximal medical therapy and medically-supervised diets
Exclusion Criteria:
  • Esophageal Stricture
  • Marginal Ulcer at the gastrojejunostomy anastomosis
  • Non-compliance with bariatric follow-up
  • Gastric ulcers
  • Paraesophageal hernias

Detailed Description

The most effective weight loss procedures in the United States are both roux-en-Y gastric
bypass (RYGB) and sleeve gastrectomy (SG)where the majority are performed laparoscopically.
Estimated excess body weight loss (EBWL) is >50% at the end of one year. However, nearly 20%
of patients fail to meet the estimated EBWL or they may experience weight gain recidivism.
The first step is nutritional counseling, medically supervised diets, and medical therapy.
Surgery would be for those who still fail to lose weight despite the aforementioned efforts.
It is hypothesized that failure of weight loss for RYGB is gastrojejunostomy (GJ) dilation
defined as >2 cm. Surgical treatment would require revision of this dilation. Unfortunately
many of these revision procedures cannot be done laparoscopically given dense intra-abdominal
adhesions. This will require conversion to an open surgery in a morbidly obese patient thus
raising postoperative morbidity and mortality estimated to range between 15%-50%.
The investigators propose to use the endoscopic suturing device designed by Apollo
EndoSurgery to decrease the GJ dilation to 5-6 mm thus causing restriction, delayed food
transit time, and promote early satiety. These efforts will limit overall caloric intake
thereby promoting weight loss.
It is thought that patients with previous SG may have a dilation of their stomach. The
investigators propose a pyloric cerclage using the Apollo EndoSurgery suturing device by
decreasing the opening of the pylorus thus achieving the same goals that the investigators
proposed above with RYGB revision.
Endoscopic procedures are same day procedures with little morbidity and mortality when
compared to laparoscopic or open bariatric surgery revision.


Final eligibility is determined by the health professionals conducting the trial and the protocol approved by the Committee on Human Resources (CHR) at the University of California, San Francisco (UCSF). The Patient Consent Form for this trial is available upon request. For more information about this trial, please see the full posting at

Information about this trial was obtained from the NIH Clinical Trials website, on 9/20/2018. UCSF specific information including the PI (Principal Investigator), trial enrollment status, and UCSF Study ID, supplement the study posting.

Site Directory